US Patent

US10363224 — Extended-release topiramate capsules

Method of Use · Assigned to Upsher Smith Laboratories LLC · Expires 2033-03-19 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an extended-release topiramate capsule with a specific design that includes a core of topiramate mixed throughout and a coating with one or more release controlling agents.

USPTO Abstract

An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Drugs covered by this patent

Topamax (topiramate) · Janssen

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-766`	—	Topamax
`U-766`	—	Topamax
`U-766`	—	Topamax
`U-766`	—	Topamax
`U-766`	—	Topamax

Patent Metadata

Patent number: US10363224
Jurisdiction: US
Classification: Method of Use
Expires: 2033-03-19
Drug substance claim: No
Drug product claim: No
Assignee: Upsher Smith Laboratories LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.